Generic medicine is still the main drug for patients in China, but its development faces new challenges

[pharmaceutical network market analysis] in recent years, it is obvious to all that it is difficult and expensive for people to see a doctor In order to solve the problem of high drug price as an important cause, a series of policies and measures aimed at reducing drug price have been released intensively, which has attracted much attention The industry said, "in recent years, support for innovation does not change that generic drugs remain the main body of patient medication in China for several years In the future, generics will still be the main body and there will be a broad market, because patients' needs are the fundamental driving force " For a long time, the pharmaceutical industry in China has always been "dominated by imitation" According to the statistical data of "analysis report on market prospect and investment strategic planning of China's generic drug consistency evaluation" issued by the prospective industry research institute, 99% of 5000 pharmaceutical factories in China are generic pharmaceutical enterprises; Of the 189000 drug approvals, 95% are generic drugs It can be said that generic drugs play a leading role in the development of China's pharmaceutical industry However, some insiders pointed out that although generic drugs are still the main body, under the influence of policies such as "4 + 7" volume purchase, medical insurance fee control and two vote system, generic drugs are facing the pressure of sharp decline in product sales and price Some enterprises began to adjust the product layout of the company and abandon some generic drugs business to adapt to the market development The shuffle of generic pharmaceutical market is going on, how should enterprises actively respond? According to the industry, in this process, the integrated enterprise of raw material preparation with cost advantage will take the lead "The national drug consistency evaluation, organizing the centralized procurement of pharmaceuticals is mainly for the purpose of achieving full competition between the original research and generic drugs, through the purchase of quantity, the volume of price changes, the improvement of the drug price market formation mechanism, the promotion of drug price reduction and quality improvement, and the realization of medical insurance burden reduction and synergy The future generic drug companies will further squeeze out the price bubble." It is understood that under this trend, some enterprises also began to actively respond For example, as one of the early domestic enterprises to carry out the export business of characteristic intermediates and APIs, Haixiang pharmaceutical's Penan series and clindamycin series have strong market advantages in terms of scale, quality, technology, etc It is reported that Haixiang pharmaceutical industry has entered the supplier system of many original research and brand generic pharmaceutical enterprises, and the cooperation of joint declaration and conformity evaluation with pharmaceutical enterprises in the domestic market has also made positive progress "In this view, as far as the irreversible price reduction trend of generic drugs is concerned, Haixiang pharmaceutical industry has better production control advantage, strong resistance to market changes and high risk resistance, which provides a good driving force for the company's rapid and stable development." Some analysts pointed out The listing of generic drugs is a good thing for the common people It can make everyone affordable and use good drugs Due to various reasons, China's generic industry is large but not strong The market of high-quality drugs is mainly occupied by foreign original research drugs The price of some original research drugs is falsely high Compared with the accessibility and affordability of current drugs, the demand for high-quality generic drugs by the majority of the people still lags behind The pilot work of centralized purchase and use of drugs organized by the state should also be promoted nationwide, so as to make the drug price separate from "puffiness" For pharmaceutical enterprises, centralized purchasing with volume will usher in an industry reshuffle Those enterprises that previously depended on a certain terminal market and channel barriers will face challenges, but it is a good opportunity for some enterprises Centralized procurement has squeezed out the gray profit part of the previous circulation link, leaving the reasonable profit of generic drugs At the same time, China's generic drug enterprises also need to improve the formulation, excipients, preparation process and other aspects of generic drugs, and the implementation of consistency evaluation has an optimization effect on the market, which will promote the quality of generic drugs to continue to improve According to the industry, if generic drugs are to be trusted by more patients and doctors, they must also pass the "consistency evaluation"